Aesthetics Has a Theranos Problem
When a Medical Story Outruns the Evidence Beneath It
Parallels: what aesthetics can learn from industries that have nothing to do with it.
Theranos was, for the better part of a decade, one of the most compelling stories in medicine. It was built on the promise that a single drop of blood from a finger prick could run hundreds of diagnostic tests. The founder delivered it with a conviction, a black turtleneck, and a Stanford-dropout mythology that gave the whole enterprise the texture of inevitability. At its height it was valued at roughly nine billion dollars, partnered with national pharmacy chains, and stocked with a board of former statesmen. None of it was supported by a technology that actually worked as claimed. The proprietary device could not reliably do what the story said it did, and the company ran many of its tests on conventional machines while implying otherwise. The entire edifice held up on the narrative rather than the science. The story was irresistible, and the people repeating it wanted it to be true. When a persistent journalist and a handful of internal skeptics finally forced the evidence into daylight, the company collapsed with startling speed. The lesson it left behind is one that aesthetics, of all industries, should study most carefully, because aesthetics runs on exactly the combination that made Theranos possible: a compelling medical story and an audience predisposed to believe it.
Finish the essay. Join the MargaZine.
The MargaZine is free. One email unlocks the full library and brings every Monday drop to your inbox. No spam; unsubscribe anytime.
The credibility was borrowed, not earned
What made Theranos so durable for so long is that it wrapped an unproven claim in every available signal of medical legitimacy: the credentialed advisors, the regulatory language, the gravity of a health mission. The story arrived pre-authenticated, its seriousness vouched for by everything around it except the one thing that mattered, which was data that could withstand scrutiny. This is the crucial mechanism. Medical credibility can be assembled from borrowed signals rather than earned from evidence. An audience will accept the borrowed version for a remarkably long time, especially when the claim is exciting and the alternative is the tedious work of verification. The story was doing more than sitting on top of a real product. The story was substituting for the product, and it worked precisely because it was dressed in the vocabulary and the trappings of rigor while lacking the rigor itself.
Aesthetics is built for this failure mode
Aesthetics should find this uncomfortably familiar. It is a field where a compelling story and the appearance of medical seriousness routinely travel ahead of the evidence, and where the audience, patients and providers alike, is strongly predisposed to believe an exciting claim wrapped in scientific language. The regenerative narrative is the clearest current example. The vocabulary of serious biology, the borrowed pedigree of legitimate medical applications, and the atmosphere of scientific inevitability frequently arrive well ahead of the aesthetic evidence that would justify them. A treatment can be sold on a story that sounds authenticated while resting on data that is still maturing. The parallel is structural rather than a charge of fraud, which the overwhelming majority of aesthetic companies never commit. A category whose conditions are an exciting medical story, a believing audience, and the difficulty of verification is built for a narrative to outrun its evidence. It therefore demands more skepticism of its own claims than it is accustomed to applying.
The correction is the part worth fearing
The most important thing Theranos demonstrates is what happens at the end. A claim that outruns its evidence rarely deflates quietly. It holds until reality forces the issue, and then it collapses all at once, taking a great deal of adjacent trust down with it. This is the mechanism that should worry an industry already prone to fragile trust and periodic fear. The gap between an exciting medical story and the evidence beneath it is a deferred reckoning rather than a stable arrangement. The longer the gap persists and the more the story is believed, the more violent the correction when the evidence finally catches up. The companies that will endure are the ones that close the gap deliberately. They earn their credibility from evidence rather than borrowing it from signals, and they resist the enormous pull, in a believing market, to let a good story do the work only good data should.
The danger of a medical narrative outrunning its evidence is not a distant abstraction in aesthetics. It is a live and structural risk in a field built on exciting claims and a believing audience. Helping companies tell a story their evidence can actually support, and close the gap between what is promised and what is proven before reality closes it for them, is a central part of what I do, particularly in the regenerative and biostimulatory space where the temptation to borrow credibility is strongest. If your positioning leans on a story running ahead of your data, that gap is worth measuring honestly now rather than discovering it at the moment it corrects, and it is a good place to begin a conversation.
Schedule a consultationA pharmacist turned commercial leader who has followed products across the entire value chain — from clinical development to launch, loyalty, and lifecycle — at three of the industry’s largest names.
Work with Marga →References & further reading
- Theranos: a compelling medical story that outran the evidence beneath it. Source.
The frameworks and commercial analysis here are Marga Partners’ own; the factual claims rest on the sources cited.